Genescà, EulàliaMorgades, MireiaGonzález Gil, CeliaFuster Tormo, FranciscoHaferlach, ClaudiaMeggendorfer, ManjaMontesinos, PauBarba, PereGil, CristinaColl, RosaMoreno, María JoséMartínez Carballeira, DanielGarcía Cadenas, IreneVives, SusanaRibera, JordiGonzález Campos, JoséDíaz Beyà, MarinaMercadal, SantiagoArtola, María TeresaCladera, AntoniaTormo, MarBermúdez, AranchaVall Llovera, FerranMartínez Sánchez, PilarAmigo, María LuzMonsalvo, SilviaNovo, AndrésCervera, MartaGarcía Guiñon, AntonioCiudad, JuanaCervera, JoséHernández Rivas, Jesús MaríaGranada, IsabelHaferlach, TorstenOrfao, AlbertoSolé, FrancescRibera, Josep Maria2021-10-042021-10-042021-10-010145-2126https://hdl.handle.net/2445/180372The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.7 p.application/pdfengcc by-nc-nd (c) Genescà, Eulàlia et al, 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/Citogenètica humanaLeucèmiaPronòstic mèdicHuman cytogeneticsLeukemiaPrognosisinfo:eu-repo/semantics/article2021-10-01info:eu-repo/semantics/openAccess34139642